273 related articles for article (PubMed ID: 25072509)
1. Pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for erythropenia in rats.
Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
J Pharmacol Toxicol Methods; 2014; 70(2):134-44. PubMed ID: 25072509
[TBL] [Abstract][Full Text] [Related]
2. Semi-physiological pharmacokinetic-pharmacodynamic (PK-PD) modeling and simulation of 5-fluorouracil for thrombocytopenia in rats.
Kobuchi S; Ito Y; Hayakawa T; Nishimura A; Shibata N; Takada K; Sakaeda T
Xenobiotica; 2015 Jan; 45(1):19-28. PubMed ID: 25050790
[TBL] [Abstract][Full Text] [Related]
3. Semi-physiological pharmacokinetic-pharmacodynamic modeling and simulation of 5-fluorouracil for the whole time course of alterations in leukocyte, neutrophil and lymphocyte counts in rats.
Kobuchi S; Ito Y; Hayakawa T; Kuwano S; Baba A; Shinohara K; Nishimura A; Shibata N; Takada K
Xenobiotica; 2014 Sep; 44(9):804-18. PubMed ID: 24650147
[TBL] [Abstract][Full Text] [Related]
4. Population Pharmacokinetic-Pharmacodynamic Modeling of 5-Fluorouracil for Toxicities in Rats.
Kobuchi S; Ito Y; Sakaeda T
Eur J Drug Metab Pharmacokinet; 2017 Aug; 42(4):707-718. PubMed ID: 27889876
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetic and pharmacodynamic modeling of recombinant human erythropoietin after intravenous and subcutaneous administration in rats.
Woo S; Krzyzanski W; Jusko WJ
J Pharmacol Exp Ther; 2006 Dec; 319(3):1297-306. PubMed ID: 16973883
[TBL] [Abstract][Full Text] [Related]
6. A predictive biomarker for altered 5-fluorouracil pharmacokinetics following repeated administration in a rat model of colorectal cancer.
Kobuchi S; Kuwano S; Imoto K; Okada K; Nishimura A; Ito Y; Shibata N; Takada K
Biopharm Drug Dispos; 2013 Oct; 34(7):365-76. PubMed ID: 23836081
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetic-pharmacodynamic modeling of diltiazem in spontaneously hypertensive rats: a microdialysis study.
Bertera FM; Mayer MA; Opezzo JA; Taira CA; Bramuglia GF; Höcht C
J Pharmacol Toxicol Methods; 2007; 56(3):290-9. PubMed ID: 17560132
[TBL] [Abstract][Full Text] [Related]
8. Comparison of different pharmacodynamic models for PK-PD modeling of verapamil in renovascular hypertension.
Bertera FM; Mayer MA; Opezzo JA; Taira CA; Höcht C
J Pharmacol Toxicol Methods; 2008; 57(3):212-9. PubMed ID: 18442930
[TBL] [Abstract][Full Text] [Related]
9. Population analysis of the pharmacokinetics and the haematological toxicity of the fluorouracil-epirubicin-cyclophosphamide regimen in breast cancer patients.
Sandström M; Lindman H; Nygren P; Johansson M; Bergh J; Karlsson MO
Cancer Chemother Pharmacol; 2006 Aug; 58(2):143-56. PubMed ID: 16465545
[TBL] [Abstract][Full Text] [Related]
10. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
11. Comparison of 5-fluorouracil pharmacokinetics in whole blood, plasma, and red blood cells in patients with colorectal cancer.
Wattanatorn W; McLeod HL; Macklon F; Reid M; Kendle KE; Cassidy J
Pharmacotherapy; 1997; 17(5):881-6. PubMed ID: 9324177
[TBL] [Abstract][Full Text] [Related]
12. Population pharmacokinetic modelling and simulation of 5-fluorouracil incorporating a circadian rhythm in rats.
Kobuchi S; Ito Y; Nakano Y; Sakaeda T
Xenobiotica; 2016 Jul; 46(7):597-604. PubMed ID: 26503235
[TBL] [Abstract][Full Text] [Related]
13. Comparison of 5-fluorouracil pharmacokinetics in patients receiving continuous 5-fluorouracil infusion and oral uracil plus N1-(2'-tetrahydrofuryl)-5-fluorouracil.
Ho DH; Pazdur R; Covington W; Brown N; Huo YY; Lassere Y; Kuritani J
Clin Cancer Res; 1998 Sep; 4(9):2085-8. PubMed ID: 9748123
[TBL] [Abstract][Full Text] [Related]
14. Translational Pharmacokinetic-Pharmacodynamic Modeling and Simulation: Optimizing 5-Fluorouracil Dosing in Children With Pediatric Ependymoma.
Daryani VM; Patel YT; Tagen M; Turner DC; Carcaboso AM; Atkinson JM; Gajjar A; Gilbertson RJ; Wright KD; Stewart CF
CPT Pharmacometrics Syst Pharmacol; 2016 Apr; 5(4):211-221. PubMed ID: 27104090
[TBL] [Abstract][Full Text] [Related]
15. Pharmacokinetics and concentration-effect analysis of intravenous RGD891, a platelet GPIIb/IIIa antagonist, using mixed-effects modeling (NONMEM).
Zannikos PN; Rohatagi S; Jensen BK; DePhillips SL; Rhodes GR
J Clin Pharmacol; 2000 Oct; 40(10):1129-40. PubMed ID: 11028252
[TBL] [Abstract][Full Text] [Related]
16. Pharmacokinetic/pharmacodynamic modeling of 5-fluorouracil by using a biomarker to predict tumor growth in a rat model of colorectal cancer.
Kobuchi S; Ito Y; Okada K; Imoto K; Kuwano S; Takada K
J Pharm Sci; 2013 Jun; 102(6):2056-2067. PubMed ID: 23592368
[TBL] [Abstract][Full Text] [Related]
17. Semiphysiological model for the time course of leukocytes after varying schedules of 5-fluorouracil in rats.
Friberg LE; Freijs A; Sandström M; Karlsson MO
J Pharmacol Exp Ther; 2000 Nov; 295(2):734-40. PubMed ID: 11046112
[TBL] [Abstract][Full Text] [Related]
18. Circadian rhythm of 5-fluorouracil population pharmacokinetics in patients with metastatic colorectal cancer.
Bressolle F; Joulia JM; Pinguet F; Ychou M; Astre C; Duffour J; Gomeni R
Cancer Chemother Pharmacol; 1999; 44(4):295-302. PubMed ID: 10447576
[TBL] [Abstract][Full Text] [Related]
19. Preclinical pharmacokinetic/pharmacodynamic/efficacy relationships for alisertib, an investigational small-molecule inhibitor of Aurora A kinase.
Palani S; Patel M; Huck J; Zhang M; Balani SK; Yang J; Chen S; Mettetal J; Manfredi M; Shyu WC; Ecsedy JA; Chakravarty A
Cancer Chemother Pharmacol; 2013 Dec; 72(6):1255-64. PubMed ID: 24101146
[TBL] [Abstract][Full Text] [Related]
20. Nociceptive stimulus modality-related difference in pharmacokinetic-pharmacodynamic modeling of morphine in the rat.
Shang GW; Liu DN; Yan LH; Cui XY; Zhang KP; Qi C; Chen J
Pharmacol Biochem Behav; 2006 Oct; 85(2):464-73. PubMed ID: 17126387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
